Lexeo Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Lexeo Therapeutics, Inc. | LXEO - NASDAQ |
$13.00-$15.00 | $11.00 | $9.50 | 9.1 million | 11/3/2023 |
| J.P. Morgan, Leerink Partners, Stifel, RBC Capital Markets | ||||||
Co-Manager(s): Chardan | ||||||
| Health Care | ||||||
Filing(s): Filed 2023-09-29 Terms Added 2023-10-30 | ||||||
Lexeo Therapeutics, Inc. Quote & Chart - Click for current quote - LXEO
IPO Boutique aggregates information on public companies and private companies, such as "LXEO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Lexeo Therapeutics, Inc. (adapted from Lexeo Therapeutics, Inc. prospectus):
They are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "LXEO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.